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Abstract
Non-alcoholic fatty liver disease (NAFLD) affects 20–30% of the population, 
with an increased prevalence in industrialized regions. Some patients with NAFLD 
develop an inflammatory condition termed non-alcoholic steatohepatitis (NASH) 
that is characterized by hepatocellular injury, innate immune cell-mediated inflam-
mation, and progressive liver fibrosis. In clinical practice, abdominal imaging, 
which reveals hepatic steatosis, is sufficient for NAFLD diagnosis if other diseases 
have been rejected. However, a liver biopsy is needed to differentiate NASH from 
simple steatosis. Therapeutic strategies used to treat obesity and metabolic syn-
drome improve NAFLD, but there is no specific treatment effective for NASH. The 
gut microbiota (GM) is composed of millions of microorganisms. Changes in the 
GM have a significant impact on host health. Intestinal dysbiosis is an imbalance 
in the GM that can induce increased permeability of the epithelial barrier, with 
migration of GM-derived mediators through portal vein to the liver. These media-
tors, such as lipopolysaccharides, short-chain fatty acids, bile acids (BAs), choline, 
and endogenous ethanol, seem to be involved in NAFLD pathogenesis. Given this 
evidence, it would be interesting to consider GM-derived mediator determination 
through omics techniques as a noninvasive diagnostic tool for NASH and to focus 
research on microbiota modulation as a possible treatment for NASH.
Keywords: non-alcoholic fatty liver disease, non-alcoholic steatohepatitis,  
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1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is currently the most prevalent 
chronic liver disease worldwide [1]. A subset of NAFLD patients have the pro-
gressive form of NAFLD termed non-alcoholic steatohepatitis (NASH). NASH is 
typically characterized by a specific pattern on liver histology, including steatosis, 
lobular inflammation, and ballooning with or without perisinusoidal fibrosis [2]. It 
can progress to advanced fibrosis, cirrhosis, hepatocellular carcinoma, and liver-
related morbidity and mortality. Liver disease is only the third leading cause of 
death in patients with NAFLD, following cardiovascular disease and malignancy [3].
Precise histological diagnosis of NAFLD is commonly based on liver biopsy 
[4]; however, biopsies present several potential problems [5]. Thus, there is a need 
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for reliable and cost-effective noninvasive biomarkers to avoid the invasiveness  
of biopsy [6].
Although there are some clinical strategies to ameliorate NAFLD progression, 
such as treatments for obesity or type 2 diabetes mellitus (T2DM), there is no medi-
cation proven to be effective as a treatment for NASH [7]. Therefore, it is necessary 
to improve the research on possible therapeutic targets for NASH due to the severity 
of this pathological condition.
Previous evidences have linked gut dysbiosis with obesity, insulin resistance 
(IR), metabolic syndrome (MS), and NAFLD [8, 9]. The impact of the GM on 
NAFLD/NASH has been attributed to increased gut permeability, intestinal 
endotoxemia, endogenous alcohol production, upregulation of hepatic de novo 
lipogenesis and triglyceride synthesis, reduction in choline metabolism, and 
aggravation of IR [10]. The increased permeability of the intestinal barrier results 
in the release of substances such as lipopolysaccharides (LPS), bacterial compo-
nents, short-chain fatty acids (SCFAs), bile acids (BAs), choline metabolites, and 
endogenous ethanol that reach the liver and seem to contribute to the pathogenesis 
of NAFLD (Figure 1) [11, 12]. It is important to note that some of these substances 
could perhaps be employed as potential noninvasive biomarkers of NAFLD 
progression.
Manipulation of the microbiota through probiotics, prebiotics, and antibiotic 
treatment yields encouraging results for the treatment of obesity, T2DM, and 
NASH in animal models, but data in humans are scarce. In regard to NAFLD, this 
Figure 1. 
Implication of intestinal dysbiosis in NAFLD pathogenesis. Short-chain fatty acids (SCFAs), bile acids (BAs), 
lipopolysaccharides (LPS), trimethylamine-N-oxide (TMAO), ethanol (EtOH), non-alcoholic fatty liver 
(NAFL), and non-alcoholic fatty liver disease (NAFLD).
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therapeutic strategy seeks to prevent the endotoxicity produced by the microbi-
ota-derived metabolites that reach the liver and promote the progression of the 
disease [13]. Thus, there is a need to focus research on the GM as a therapeutic 
target to ameliorate NASH.
To provide a broad overview of the relationship between intestinal dysbiosis 
and NAFLD, we have elaborated on this subject in this book chapter. In this sense, 
this narrative chapter will explain (a) non-alcoholic fatty liver disease, (b) the gut 
microbiota, (c) gut microbiota-derived mediators involved in NAFLD, and (d) the 
gut microbiota as a therapeutic target in NAFLD.
2. Non-alcoholic fatty liver disease
NAFLD has emerged as the most common form of chronic liver disease world-
wide. The incidence of NAFLD has drastically increased in parallel with obesity in 
recent years. Currently, the global prevalence of NAFLD is approximately 25% [1], 
but it can increase to 58% in individuals who are overweight or as high as 98% in 
individuals with nondiabetic morbid obesity [14].
NAFLD comprises a spectrum of disorders extending from simple steatosis 
(SS) to NASH, fibrosis, and cirrhosis [2, 15]. This pathology has potentially serious 
sequelae [16]. Although SS tends to develop into a favorable clinical course [3], 
NASH can develop into liver cirrhosis and hepatocellular carcinoma [15]. Thus, 
liver-related mortality increases exponentially with an advance in the fibrosis stage 
[17]. In this regard, NASH is a very common cause of liver transplant worldwide [1]. 
Although the most common cause of death in patients with NAFLD is cardiovas-
cular disease, independent of other metabolic comorbidities, NAFLD is becoming 
a major cause of liver disease-related morbidity (e.g., cirrhosis, end-stage liver 
disease, hepatocellular carcinoma, and liver transplantation).
NAFLD is characterized by significant lipid deposition in the hepatocytes of the 
liver parenchyma [18]. Obesity, T2DM, dyslipidemia, MS, and IR are the main risk 
factors for NAFLD [19]. Most NAFLD patients are asymptomatic, and the evidence 
of hepatic steatosis should be detected via a routine blood test, showing a deregula-
tion in liver enzymes. Currently, it is not possible to diagnose NAFLD with only 
a blood test, but the aspartate aminotransferase (AST)-alanine aminotransferase 
ratio (ALT) can be used as a first step [20–22]. However, the ALT level correlation 
with histological findings has poor sensitivity and specificity for the diagnosis of 
NASH [23]. Then, it is necessary to rule out other causes of liver damage, such as 
alcoholic fatty liver disease, drug-induced liver injury, viral hepatitis, autoimmune 
liver disease, hemochromatosis, celiac disease, and Wilson’s disease [1]. Finally, 
ultrasonography is the most common noninvasive tool used to detect NAFLD. There 
are also other imaging techniques used to detect liver steatosis, such as computer 
tomography or magnetic resonance imaging, but ultrasound is the technique that 
provides the most information without irradiation [24, 25].
One-third of the NAFLD-affected subjects progress to NASH. This condition is 
characterized by the presence of hepatocellular ballooning and inflammation and 
has a prevalence of 2–3% worldwide [2]. Key issues in NAFLD patients are the dif-
ferentiation of NASH from SS and the identification of advanced hepatic fibrosis. 
To date, liver biopsy has been the gold standard for identifying these two critical end 
points but has well-known limitations, including invasiveness; rare but potentially 
life-threatening complications; poor tolerance; sampling variability; and cost. 
Furthermore, due to the epidemic proportion of individuals with NAFLD world-
wide, liver biopsy evaluation is impractical, and noninvasive assessment for the 
diagnosis of NASH and fibrosis is needed [5]. NASH is confirmed when the hepatic 
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tissue shows the presence of perilobular inflammation, hepatocellular ballooning, 
Mallory’s hyaline, and acidophil bodies with or without fibrosis. Although there 
are other noninvasive tests, such as the fatty liver index, NAFLD fibrosis score, 
and FibroMeter, and elastographic techniques, such as FibroScan, that can suggest 
the presence of NASH and detect fibrosis [15], a precise histological diagnosis of 
NASH is commonly based on liver biopsy [26]. The development of alternative 
noninvasive strategies has been an area of intensive research over the past decade 
and currently.
Regarding NAFLD therapeutics, all forms of treatment of metabolic disorders 
are able to modify liver damage. Diet and lifestyle modification and insulin-
sensitizing agents appear to be promisingly effective against NAFLD progression. 
However, these approaches may not be effective in some patients. Many other 
drugs are currently being studied to establish treatments for NAFLD. At present, 
no accepted drug treatment for NASH has been stated [24]. In this sense, it is very 
important to improve the knowledge of NAFLD physiopathology. Actually, the 
underlying precise mechanisms of NAFLD pathogenesis have just begun to be 
understood. The classic “multiple hit” theory states that lipid accumulation initi-
ates hepatic steatosis and subsequently triggers multiple insults acting together 
(hormones/adipokines from adipose tissue, inflammation, deregulated fat metabo-
lism, lipotoxicity, oxidative stress, mitochondrial dysfunction, and genetic and 
epigenetic factors), ultimately inducing NASH and cirrhosis [27]. Progression to 
NASH is linked to systemic inflammation, and it is associated with other pathologi-
cal processes, such as innate immunity alterations, endoplasmic-reticulum stress, 
toll-like receptor (TLR) signaling, mitochondrial dysfunction, and intestinal 
dysbiosis [6, 28–32]. Regarding this last process, approximately 70–75% of blood 
that reaches the liver comes from the portal vein circulation that communicates 
the liver with the intestine [33]. The liver is continually exposed to GM-derived 
mediators, including bacteria and bacterial components, such as LPS, promoting 
an inflammatory response that contributes to liver injury [13].
3. The gut microbiota
Millions of symbiotic microorganisms live on and within human beings and play 
an important role in human health and disease. Initial colonization occurs at the 
time of birth, and humans progressively acquire ∼1014 bacterial cells at equilibrium, 
which remain for life [13].
The human microbiota, especially the GM, has even been considered to be an 
“essential organ,” carrying approximately 150 times more genes than the human 
genome [34]. The GM is composed of an immense number of microorganisms 
(bacteria, viruses, and fungi) with several functions, such as host nutrition, bone 
mineralization, immune system regulation, xenobiotic metabolism, proliferation of 
intestinal cells, and protection against pathogens [35, 36]. This bacterial community 
is dominated by anaerobic bacteria and includes 500–1000 species [37]. Firmicutes 
and Bacteroidetes are the most important phyla among the intestinal bacteria, with a 
proportion of over 90% of the total community [38].
The duodenum and proximal jejunum normally contain small numbers of bacte-
ria, usually lactobacilli and enterococci, which are facultative anaerobes. The distal 
ileum is a transition zone between sparse populations of aerobic bacteria of the 
proximal small intestine and very dense populations of anaerobic microorganisms 
in the large bowel. Occasional groups of bacteria can be found in low concentra-
tions within the lumen of the small intestine. Bacteria do not form clusters, and the 
luminal contents are separated from the mucosa by a mucus layer [13].
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The GM is specific to an individual and highly resilient to changes. However, 
it can be affected by several factors, intrinsic and extrinsic to the host, such as the 
subject’s genetic makeup, dietary habits, antibiotic use, and environmental changes 
[13, 39, 40]. A disruption in the composition of the normal GM is known as intesti-
nal dysbiosis [41, 42]. Generally, this process includes an unfavorable change in the 
bacterial composition, with a reduction in autochthonous bacteria and growth of 
others that prejudice host health [43].
3.1 Intestinal dysbiosis
Intestinal dysbiosis is a process that may adversely impact metabolism and 
produce immune responses, favoring NAFLD progression. Important studies on the 
relationship of the GM with obesity have identified profound changes in the composi-
tion and metabolic function of the GM in subjects with obesity. Moreover, these stud-
ies demonstrated that the GM interacts with host epithelial cells to indirectly control 
energy expenditure and storage and activate inflammatory responses in NASH 
pathogenesis [44]. Qualitative or quantitative imbalances in the GM might have seri-
ous health consequences for the host, including small intestinal bacterial overgrowth 
(SIBO) syndrome [13]. Due to gut dysbiosis, there is an elevated production of toxic 
bacterial components and metabolic mediators, which consequently accumulate in 
the intestine. In addition, an increase in intestinal permeability and further disrup-
tion of the epithelial barrier lead to the release of these GM-derived mediators [42], 
which could reach the liver through portal circulation, favoring hepatic inflamma-
tion and the development of NAFLD [45, 46]. After disruption of the gut epithelial 
barrier, the liver is exposed to microbial products and metabolites resulting from 
bacterial metabolism [47, 48]. In this sense, it has been demonstrated that patients 
with NAFLD have gut dysbiosis, gut epithelial barrier dysfunction, and increased 
translocation of bacterial components to the liver [49]. For this reason, mediators 
derived from gut dysbiosis might also be related to the pathogenesis of the disease. 
Several previous studies in clinical settings have associated intestinal dysbiosis with 
the occurrence of NAFLD [50–52] and with the progression to NASH [10, 53].
Among the various factors, dietary habits are considered to be most influential 
on the gut microbiome in subjects with obesity and NAFLD patients. It is well-
known that a high-fat diet causes gut dysbiosis characterized by lowered species 
richness and changes in microbial composition, such as decreased Bacteroidetes 
and increased Firmicutes and Proteobacteria abundances [43]. On the other hand, 
Prevotella, a member of the phylum Bacteroidetes, is associated with plant-rich 
diets. Prevotella-dominated microbiotas have higher fiber utilizing capacity than 
Bacteroides-dominated microbiotas, producing higher amounts of SCFAs [54]. 
There are some studies that consider Prevotella to be a beneficial commensal bacte-
rium [10, 55], but there are others that noted enriched fecal Prevotella in NASH or 
cirrhotic patients [56–58]. These contradictory results may be partly explained by 
the differences in populations, age, or NAFLD stages between the studies. In this 
sense, further studies on Prevotella should be directed to characterize properties at 
the species level and to evaluate these species in different stages of NAFLD.
GM-derived mediators resulting from intestinal dysbiosis could play a key role 
in NAFLD progression through several mechanisms: (1) enhanced energy extrac-
tion from food nutrients by formation of SCFAs; (2) modulation of BA synthesis, 
which is crucial for fat absorption and affects metabolism of glucose via farnesoid 
X receptor (FXR); (3) innate immune system activation by bacterial component 
translocation; (4) endogenous ethanol production; and (5) reduction in choline 
metabolism, which reduces efflux of very-low-density lipoprotein (VLDL) from 
hepatocytes, promoting inflammation. These mechanisms involve translocation 
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of these mediators, such as SCFAs, BAs, endogenous ethanol, and choline metabo-
lites, which may be potentially evaluated as noninvasive blood markers of NAFLD 
progression [59].
4. Gut microbiota-derived mediators involved in NAFLD
4.1 Short-chain fatty acids
SCFAs are molecules with seven carbon atoms or less, for example, acetic, pro-
pionic, and butyric acids, that are produced by the gut bacterial fermentation of 
cellulose, xylans, resistant starch, or inulin since humans lack enzymes that digest 
fibers. These substances can strongly regulate host metabolism [60]. In general, 
these SCFAs have several effects on energy metabolism, the immune response, 
and adipose tissue expansion and act as signaling molecules between the GM and 
the host. SCFAs provide not only important sources of nutrients and energy for 
the intestinal epithelium but also serve as precursors for lipogenesis and gluco-
neogenesis [61, 62]. SCFAs can directly act as lipid precursors in the liver and 
mediate other effects as ligands for G protein-coupled receptors, specifically the 
subtypes GPR41 and GPR43 [59]. Experimental studies have demonstrated that 
these SCFAs can modulate regulatory T-cell expansion and enhance neutrophil 
chemotaxis, promoting inflammation in mouse models [63–66]. Furthermore, 
SCFAs modulate the production of several inflammatory cytokines, including 
tumor necrosis factor (TNF)-α, interleukin 2 (IL-2), interleukin 6 (IL-6), and 
interleukin 10 (IL-10) [67]. Recently, some studies found that high concentrations 
of intestinal SCFAs as a result of dysbiosis and their G-protein coupled recep-
tors play an important role in NAFLD progression [68, 69]. Activation of GPR41 
and GPR43 stimulates secretion of peptide-YY, inhibits gut motility, and slows 
intestinal transit. Therefore, nutrient absorption and energy capture from the diet 
increase and may promote hepatic lipogenesis [56, 70]. Additionally, activation of 
GPR41 and GPR43 induces secretion of glucagon-like peptide-1 (GLP-1), which 
activates genes in hepatocytes that regulate fatty acid β-oxidation and insulin 
sensitivity [56, 71], promoting NAFLD occurrence and progression. Furthermore, 
clinical studies have demonstrated SCFA enrichment in fecal samples of children 
and adults with NAFLD [72, 73].
However, other previously published studies have reported that SCFAs could be 
beneficial in the progression of NAFLD. In this regard, butyrate activates AMP-
activated protein kinase (AMPK) in the liver and accelerates the assembly of tight 
junction proteins [74, 75], improving intestinal barrier dysfunction and reducing 
metabolic endotoxemia. In addition, butyrate is able to modulate regulatory T-cell 
activity, suppressing the immune response and reducing liver inflammation [76].
The close relationship between intestinal dysbiosis and SCFA production, 
according to the results of previous experimental and clinical studies, provides 
evidence of their potential use as markers of NAFLD progression. In this sense, in a 
recent study, we studied this possibility, but we failed to demonstrate any relation-
ship between circulating SCFA levels and histological degrees of NAFLD in a cohort 
of patients with morbid obesity [6]. However, additional studies are necessary to 
accurately determine the specific role of SCFAs in NAFLD.
4.2 Bile acids
As previously mentioned, the gut-liver axis, which involves gut hormone 
release and the immune response, is essential to regulate systemic metabolism. 
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BAs participate in communication along this axis. They are steroid-derivative 
components of bile synthesized after cholesterol oxidation by enzymes present in 
hepatocytes, and they are involved in the absorption of lipids and vitamins in bile 
salt-dependent flow regulation. BAs participate in the digestion and solubilization 
of lipids and regulate hepatic glucose and inflammation [59, 60]. Moreover, they 
are capable of controlling their own synthesis through the activation of FXR [77, 
78]. In addition, BAs act as signaling molecules that modulate several physiological 
processes, and GM dysbiosis can change BA pool characteristics through its effects 
on BA metabolism [78, 79].
The GM is a critical modulator of BA pool size and composition, and the process 
of dysbiosis could substantially alter concentrations of conjugated and/or second-
ary bile acids, as well as increase their synthesis.
Unmodified BAs, also called primary BAs (cholic acid (CA) and chenodeoxy-
cholic acid (CDCA)), undergo a deconjugation process by GM components after 
reaching the colon and become secondary BAs, such as deoxycholic acid (DCA) and 
lithocholic acid (LCA); they can be transported again to the liver via the portal vein 
in a mechanism called “enterohepatic circulation.” BAs prevent the overgrowth of 
bacteria in the gut to maintain gut homeostasis. This protective effect is mediated 
by their detergent properties and the activation of FXR, which protects the distal 
small intestine from bacterial proliferation. It is recognized that these circulating 
BAs, in addition to the abovementioned functions, can coordinate a wide number of 
pathways mediated by specific nuclear receptors (NRs) [60].
The increased intestinal permeability associated with BA modifications has 
been linked to metabolic endotoxemia, IR, and inflammatory cytokine release 
with enhanced proinflammatory signaling cascades, which are common findings 
in patients with NAFLD [59]. An increased level of BAs causes activation of the 
cell death pathway mediated by inflammatory and oxidative stress cascades in liver 
tissue [80, 81].
Regarding hepatic lipid metabolism, Watanabe et al. demonstrated that 
hepatic FXR activation mediated by BAs could induce the expression of the 
atypical NR small heterodimer partner (SHP), which promotes the inhibition 
of sterol-regulatory element-binding protein-1c (SREBP-1c), thus reducing 
hepatic synthesis of triglycerides. In addition, FXR can limit lipid accumulation 
in the liver by promoting fatty acid oxidation after the activation of peroxisome 
proliferator-activated receptor alpha (PPARα) and by the induction of plasma 
VLDL-triglyceride clearance [82–85]. FXR activation in the liver was also demon-
strated to coordinate glucose homeostasis via the inhibition of gluconeogenesis and 
glycolysis. Interestingly, the activation of FXR in the intestine can generate crucial 
endocrine feedback regulation [86]. Experimental studies have demonstrated that 
intestinal dysbiosis can modulate the activity of FXR in the intestine, affecting 
lipid metabolism in the liver [4]. Specifically, FXR not only plays an important 
role in maintaining BA levels but also regulates glucose and lipid metabolism via 
different mechanisms, such as increasing insulin sensitivity, repressing hepatic 
gluconeogenic genes, and increasing hepatic glycogen synthesis [87, 88].
Previous investigations have demonstrated a BA level increase in the biological 
fluids of patients with NASH compared to that in the biological fluids of subjects 
with healthy livers and an evident association with intestinal dysbiosis [89–91]. 
Additionally, the levels of BAs have been correlated with histopathological features, 
such as the degree of hepatic steatosis, the presence of cellular ballooning, and 
the severity of fibrosis in patients with NASH [92]. These studies confirmed the 
disruption in BA homeostasis in NASH physiopathology [65] and the correlation 
of BAs with NASH severity parameters (portal inflammation, lobular inflamma-
tion, and hepatocyte ballooning) [93]. In children with NAFLD, changes in the 
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circulating BA profile have also been reported. Troisi et al. demonstrated that serum 
BA levels decrease in early NAFLD and increase during progression to fibrosis in 
obese children. These authors postulated that BAs may have value as a noninvasive 
biomarker in pediatric NAFLD progression [83, 94]. In a previous study by our 
research group, we found that FXR jejunal expression was lower in NASH patients 
than in normal liver (NL) subjects; in regard to BAs, we also found that levels of 
glycolic acid (GCA), a primary BA, and DCA, a secondary BA, were significantly 
higher in NAFLD patients than in NL subjects [6].
Considering the numerous published experimental and clinical studies associat-
ing gut dysbiosis, BAs and NAFLD, it is expected that BAs could be proposed as 
potential noninvasive markers of the disease. For example, Svegliati-Baroni et al. 
specifically proposed DCA and LCA, which can only be produced by bacterial 
fermentation [95].
4.3 Bacterial components
The liver is exposed to potentially harmful substances derived from the gut, con-
sidered pathogen-associated molecular patterns (PAMPs), that include translocated 
bacteria, LPS, bacterial DNA, bacterial RNA, and endotoxins, which are potent 
inducers of tissue inflammation [41, 96]. These PAMPs might contribute to the 
pathogenesis of NAFLD by activating the innate immune system via TLRs, which 
recognize these gut-derived bacterial components. The healthy liver expresses low 
mRNA levels of TLRs (TLR1, TLR2, TLR4, TLR6, TLR7, TLR8, TLR9, and TLR10), 
implying a high tolerance of the liver to TLR ligands from the microbiota. The 
translocation of these bacterial components from the gut into the portal system 
is facilitated by intestinal barrier disruption due to GM dysbiosis [13, 96]. In this 
sense, there is evidence that dysbiosis causes permeability changes that increase 
portal levels of gut-derived TLR ligands (LPS or endotoxin), which further activate 
TLR4 on hepatic Kupffer and stellate cells [97]. LPS is the major structural compo-
nent of gram-negative bacteria and the major component of endotoxin. LPS may 
be recognized by LPS-binding protein (LBP) in serum and is the major activator of 
the innate immune response [98]. Ruiz et al. indicated that the serum levels of LBP 
were increased in patients with obesity and NASH compared to those in patients 
with obesity and SS and the increased serum LBP level was correlated to an upregu-
lated expression of TNF-α in liver tissue [99].
During TLR4 activation, the adaptor molecule myeloid differentiation fac-
tor 88 (MyD88) is activated, and the downstream signaling MyD88-dependent 
pathway results in the activation of necrosis factor kappa beta (NF-κB), leading to 
the expression of proinflammatory cytokines (TNF-α, IL-6, IL-8 and IL-12) and 
chemokines (interferon γ (IFN-γ) and monocyte chemotactic protein-1 (MCP-1)), 
promoting inflammation [68, 97]. There are several intracellular cascades involved 
in this process, generating oxidative stress, low-grade systemic inflammation, and 
hepatic injury [100]. In addition, TLR signaling can also lead to the production of 
inflammasomes in peripheral and parenchymal cells, which activate a variety of 
processes, including activation of caspase-1, resulting in cell death [101].
The inflammasome, which is a multimeric signaling platform that leads to the pro-
duction of IL-18 and IL-1β through the NOD-like receptors pyrin domain-containing 
(NLRP3 and NLRP6), is activated by LPS derived from intestinal dysbiosis via TLR4 
and TLR9 responses. Reports have associated inflammasome activation with the devel-
opment of liver steatosis, inflammation, and fibrosis in NAFLD patients [102, 103].
It has been shown that TLR2, TLR4, and TLR9 play an important role in the 
development of NASH [104]. In addition, other studies have established that the 
increase in endotoxin levels is related to IL-1α and TNF-α production [105, 106]. In 
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patients with NAFLD, gut permeability and SIBO due to intestinal dysbiosis have 
been associated with the severity of steatosis [107]. In biopsy-proven human NASH, 
plasma levels of IgG against endotoxin were found to be increased with NASH grade 
severity, suggesting the deleterious effect of chronic endotoxin exposure [108]. In 
our previous GM-derived metabolite study, we found overexpression of TLR9 jeju-
nal expression in NAFLD subjects, which suggested the activation of the immune 
system during NAFLD progression [6]. Additionally, enhanced expression of TLR4, 
the release of IL-8, and high levels of LPS have been demonstrated in NAFLD 
patients [109, 110]. However, other reports did not reveal an association between 
endotoxemia and NAFLD progression, suggesting that endotoxemia may not be the 
only driver of disease development in all patients [111].
Multiple experimental studies have demonstrated that a high-fat diet can 
increase the proportion of LPS derived from the GM, and administration of endo-
toxin has been shown to induce IR and weight gain [99, 112]. On the other hand, 
some authors have recently proposed that the small intestine shields the liver from 
otherwise toxic fructose exposure via the GM [113].
There is a clear relation between gut dysbiosis, bacterial-derived components, 
the inflammatory response, and NAFLD; therefore, these bacterial mediators, 
especially circulating TLRs, might be used as potential noninvasive markers of 
disease progression.
4.4 Endogenous ethanol production
Intestinal dysbiosis increases endogenous ethanol production [111], which also 
affects gut permeability, disrupting intestinal tight junctions. This process allows 
endotoxins and ethanol to reach the liver and trigger the TLR response and inflam-
masome activation, contributing to liver damage [114]. In addition to the proin-
flammatory response, ethanol promotes oxidative stress and hepatocyte necrosis 
because of the formation of reactive oxygen and nitrogen species [94]. Endogenous 
ethanol inhibits the tricarboxylic acid cycle, thus increasing levels of acetate and 
thereby promoting triglyceride accumulation in hepatocytes [64]. Ethanol can also 
increase the activity of the enzyme cytochrome P450 2E1 (CYP2E1), which cata-
lyzes the oxidation of ethanol but produces free radicals favoring oxidative damage, 
mitochondrial dysfunction, and liver inflammation [94, 115, 116].
Several studies have detected increased levels of non-dietary ethanol derived 
from bacteria in patients with obesity [111, 117] and in patients with NASH 
[111, 118, 119]. In this sense, Zhu et al. proposed that microbiomes rich in 
ethanol-producing Escherichia may be a risk factor for NAFLD progression [56]. 
Escherichia, Bacteroides, Bifidobacterium, and Clostridium can produce endog-
enous alcohol and generate significant ethanol-mediated liver damage [111]. 
Therefore, the production of endogenous ethanol by the GM may act as a hepa-
totoxin, contributing to the development of NAFLD and its progression to NASH 
[120]. In addition, children with NAFLD/NASH showed high levels of endog-
enous ethanol and LPS derived from the GM [111, 117, 121], confirming that 
endogenous ethanol might contribute to the pathogenesis of NAFLD and NASH.
Furthermore, Zhu et al. showed an increased abundance of alcohol-producing bac-
teria in NASH microbiomes, elevated blood-ethanol concentration in NASH patients, 
and the well-established role of alcohol metabolism in oxidative stress and liver inflam-
mation [56]. In our previous GM-derived metabolite study, we found an interesting 
result about the higher circulating endogenous ethanol levels in NASH patients than in 
patients with SS. This fact suggested that circulating ethanol levels could distinguish 
between different degrees of liver damage. Moreover, in the same study, we evaluated 
the diagnostic efficacy of a biomarker panel including circulating ethanol, betaine, 
Human Microbiome
10
GCA, and DCA levels as markers of NASH in a group of patients with liver histology 
indicative of NASH. A cutoff point and area under the curve were determined so that 
NASH could be diagnosed. The accuracy with which this panel discriminates NASH 
subjects from non-NASH subjects showed an area under the ROC curve (AUROC) of 
approximately 0.776 (0.632–0.921). Therefore, we concluded that the levels of certain 
circulating microbiota-related metabolites are associated with NAFLD severity and 
could be used as a “liquid biopsy” in the noninvasive diagnosis of NASH [6].
In summary, proinflammatory and prooxidative damage has been demon-
strated as a result of endogenous ethanol in the liver, which might contribute to the 
pathogenesis of NAFLD, and previous reports may support its use as a noninvasive 
biomarker of disease progression.
4.5 Reduction of choline metabolism
Choline is an essential nutrient obtained through both dietary intake and 
endogenous synthesis and is an important constituent of the phospholipid mem-
brane. The human GM actively metabolizes dietary components, including choline. 
Alterations in choline and phosphatidylcholine metabolism due to intestinal 
dysbiosis may have an impact on several physiological pathways, which could 
induce NAFLD. Choline deficiency prevents the synthesis and excretion of VLDL, 
leading to hepatic triglyceride accumulation and liver steatosis [122, 123]. In fact, 
the link between choline deficiency and the accumulation of hepatic lipids has been 
recognized for more than 50 years [124], leading to the establishment of choline-
deficient diets to induce models of NAFLD in animals.
In addition, choline can be metabolized to its derivative trimethylamine (TMA) 
by the GM. TMA reaches the liver via portal circulation and is subsequently oxi-
dized by hepatic flavin-containing monooxygenases in the liver, forming trimethyl-
amine-N-oxide (TMAO), which is then released into blood circulation [125, 126].  
Previous studies have revealed that TMAO may affect lipid absorption and choles-
terol homeostasis and modulate glucose and lipid metabolism by decreasing the 
total BA pool size [122]. TMAO modulates glucose metabolism and increases IR in 
mice fed a high-fat diet [127]. TMAO also affects lipid absorption and cholesterol 
homeostasis by reducing the conversion of cholesterol into BAs [122].
A small number of human studies have shown that the consumption of a low-
choline diet promotes fatty liver and liver damage [123, 128]. Other studies have 
pointed out that plasma-free choline levels are positively related to the severity of 
NAFLD, fibrosis, and NASH [129, 130].
On the other hand, in our previous research, we analyzed circulating levels of 
these choline metabolites according to hepatic histology and observed that levels of 
TMAO were significantly higher in NAFLD patients than in NL subjects [6], which 
correlates with the previous statement that serum TMAO levels are significantly 
higher in patients with NAFLD than in healthy people and correlates with the 
development and severity of NAFLD through different mechanisms: modulating 
glucose metabolism, promoting inflammation in adipose tissue, and influencing 
lipid absorption and cholesterol homeostasis [125, 129, 131].
In summary, the evidence has demonstrated that choline and TMAO are 
associated with the progression of NAFLD, indicating the potential use of these 
GM-derived mediators as markers of disease progression.
5. Gut microbiota as therapeutic target in NAFLD
Although there are no treatments to directly reverse steatosis, fibrosis, or liver 
damage, lifestyle changes and therapeutic strategies to treat other MS-related 
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diseases, such as obesity, T2DM, or IR, could ameliorate NAFLD, avoiding its pro-
gression to NASH. Lifestyle intervention (diet and exercise), bariatric surgery, anti-
diabetic drugs, lipid-altering agents, and antihypertensive drugs can improve all of 
the features of NASH by ameliorating MS-related diseases [4]. Nevertheless, there is 
currently no specific treatment proven to be effective in treating NASH. Clarifying 
NAFLD risk factors could lead to more accurate prediction of disease progression 
and more effective treatments based on individualized drivers of disease [132]. The 
search for a possible therapy for NASH is focused on different pathways: metabolic 
targets, cell stress and apoptosis, immune targets, fibrosis, and GM modulation.
Currently, there are different mechanisms to manage NAFLD/NASH with 
metabolic targets focused on ameliorating other related diseases but also involved in 
NAFLD progression. Moreover, vitamin E acts as an antioxidant and hepatoprotec-
tive agent used to treat NASH (Figure 2).
On the other hand, there are many active studies and clinical trials focused on 
new therapeutic strategies with different pharmacological targets to avoid NAFLD 
and NASH progression. In this regard, PPAR agonists, antidiabetic drugs, FXR 
ligands, and anti-inflammatory and antiapoptotic agents can act as insulin sensitizers 
and improve the proinflammatory chronic state characteristic of NASH; antifibrotic 
agents can avoid NASH progression to fibrosis; and GM modulation can prevent the 
intestinal dysbiosis involved in NAFLD pathogenesis (Figure 2) [4, 7, 24, 133].
The key role that the GM plays in the progression of the disease opens the door 
to new ways of thinking about NASH prevention and treatment. The possibility of 
modulating the GM to treat NAFLD and NASH has gained interest in the potential 
use of probiotics, prebiotics, and antibiotics as effective treatments.
Probiotics are defined as viable microorganisms that when administered in 
adequate amounts, confer a health benefit to the host [134]. There are many mecha-
nisms by which probiotics improve the GM and consequently ensure liver health 
(inhibition of intestinal bacterial enzymes, stimulation of host immunity, competi-
tion for limited nutrients, inhibition of bacterial mucosal adherence and epithelial 
Figure 2. 
Current and future treatment strategies to manage and treat NAFLD and NASH. Peroxisome  
proliferator-activated receptor (PPAR), farnesoid X receptor (FXR), farnesoid growth factor-19 (FGF-19), 
farnesoid growth factor-21 (FGF-21), acetyl-CoA carboxylase (ACC), glucagon-like peptide-1 receptor 
(GLP-1R), dipeptidyl peptidase-4 (DPP-4), sodium-glucose cotransporter 1/2 (SGLT-1/2), apoptosis 
signal-regulating kinase-1 (ASK-1), tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), and lysyl 
oxidase-like 2 (LXL-2).
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invasion, protection against intestinal permeability, and control of bacterial 
translocation from the gut to the portal vein circulation). The biological activity of 
probiotics depends on delivering anti-inflammatory mediators that downregulate 
proinflammatory cytokines [104]. Therefore, probiotic therapy offers an interesting 
approach to control hepatic injury and a low-grade proinflammatory state.
Another alternative is the use of prebiotic fiber, which is defined as an amount of 
nondigestible food ingredients that beneficially affect the host, by selectively stimu-
lating the growth and/or activity of one or a limited number of bacteria in the colon 
[135]. The health effects of prebiotic fiber are related to improved glucoregulation 
and modified lipid metabolism as well as selective modulation of the GM. Some 
mechanisms have been proposed to explain the beneficial effects of prebiotics 
on the accumulation of triglycerides in the liver observed in animals, including 
reduced de novo fatty acid synthesis and SCFA production, body weight and fat 
loss, and improved glycemic control, GM modulation, and anti-inflammatory 
effects [13, 104]. These promising preliminary results strongly indicate the potential 
use of probiotics and prebiotics for the prevention or treatment of NASH.
Prophylactic use of antibiotics in patients with chronic liver diseases is an 
established method of preventing infections or innate immune dysfunction in acute 
liver failure (ALF) [13]. In addition, it has been demonstrated in animal and human 
models that the positive effect of polymyxin B and metronidazole in reducing the 
severity of NAFLD during total parenteral nutrition or after intestinal bypass could 
be interesting for their use to treat NAFLD [136, 137]. However, direct evidence is 
currently lacking, and thus, antibiotics cannot be routinely recommended to treat 
NASH, although further research is needed.
Overall, to date, there have been only a few studies concerning the use of 
probiotics, prebiotics, and antibiotics in humans; therefore, large-scale randomized 
controlled trials with histological endpoints are indicated.
6. Conclusions
Intestinal dysbiosis can trigger gut inflammation and increase the permeability 
of the intestinal epithelial barrier, exposing the gut-liver axis to GM-derived media-
tors of dysbiosis, such as bacterial components or metabolites, which may induce 
hepatotoxicity, inflammation, and consequently NAFLD progression. Gut-derived 
mediators of dysbiosis contribute to NAFLD progression by activating the immune 
system, inducing oxidative stress, enhancing inflammation, and finally promoting 
fibrogenesis.
Despite the evident association between GM dysbiosis, obesity, and NAFLD 
derived from several experimental studies, few studies have been conducted in 
patients with NAFLD to explore the role of GM-derived mediators of dysbiosis 
in the occurrence and progression of the disease. Additionally, few studies have 
focused on gut-derived mediators of dysbiosis as noninvasive markers of disease 
progression. The study of these mediators may provide an opportunity to develop 
a specific diagnostic and prognostic biomarker for NAFLD and NASH. In this 
sense, we propose the metabolomic study of these mediators and other metabo-
lites involved to achieve a metabolomic profile that could be used as biomarkers 
for evaluating the status of NAFLD. On the other hand, some previous evidence 
has focused on GM modulation using probiotics, prebiotics, and antibiotics 
as therapeutic strategies to prevent or treat NAFLD and NASH, which is more 
uncertain and requires future research. In this sense, it remains important to 
promote study of GM targeting to find an effective treatment for NAFLD and 
overall for NASH.
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